Upcoming Dividend • May 21
Upcoming dividend of €0.20 per share Eligible shareholders must have bought the stock before 28 May 2026. Payment date: 01 June 2026. Payout ratio is a comfortable 34% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (3.0%). Reported Earnings • May 08
First quarter 2026 earnings released: EPS: €0.19 (vs €0.11 in 1Q 2025) First quarter 2026 results: EPS: €0.19 (up from €0.11 in 1Q 2025). Revenue: €512.3m (up 6.8% from 1Q 2025). Net income: €12.7m (up 78% from 1Q 2025). Profit margin: 2.5% (up from 1.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. New Risk • Apr 16
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.6% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Apr 16
RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, May 27, 2026 RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, May 27, 2026, at 10:00 W. Europe Standard Time. Declared Dividend • Apr 01
Dividend increased to €0.20 Dividend of €0.20 is 100% higher than last year. Ex-date: 28th May 2026 Payment date: 1st June 2026 Dividend yield will be 1.6%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 88% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Mar 31
RHÖN-KLINIKUM Aktiengesellschaft announces Annual dividend, payable on June 01, 2026 RHÖN-KLINIKUM Aktiengesellschaft announced Annual dividend of EUR 0.2000 per share payable on June 01, 2026, ex-date on May 28, 2026 and record date on May 29, 2026. Reported Earnings • Mar 27
Full year 2025 earnings released: EPS: €0.52 (vs €0.65 in FY 2024) Full year 2025 results: EPS: €0.52 (down from €0.65 in FY 2024). Revenue: €1.97b (up 5.6% from FY 2024). Net income: €34.5m (down 21% from FY 2024). Profit margin: 1.7% (down from 2.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Feb 06
Now 21% undervalued Over the last 90 days, the stock has risen 9.2% to €13.00. The fair value is estimated to be €16.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to decline by 6.1% in 2 years. Earnings are forecast to grow by 46% in the next 2 years. Reported Earnings • Nov 07
Third quarter 2025 earnings released: EPS: €0.15 (vs €0.14 in 3Q 2024) Third quarter 2025 results: EPS: €0.15 (up from €0.14 in 3Q 2024). Revenue: €498.0m (up 7.6% from 3Q 2024). Net income: €9.93m (up 4.5% from 3Q 2024). Profit margin: 2.0% (down from 2.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 08
Second quarter 2025 earnings released: EPS: €0.10 (vs €0.14 in 2Q 2024) Second quarter 2025 results: EPS: €0.10 (down from €0.14 in 2Q 2024). Revenue: €484.9m (up 5.5% from 2Q 2024). Net income: €7.01m (down 22% from 2Q 2024). Profit margin: 1.4% (down from 2.0% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 10% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.3%. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 28
Upcoming dividend of €0.10 per share Eligible shareholders must have bought the stock before 04 June 2025. Payment date: 06 June 2025. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.3%). Lower than average of industry peers (2.5%). Reported Earnings • May 09
First quarter 2025 earnings released: EPS: €0.11 (vs €0.16 in 1Q 2024) First quarter 2025 results: EPS: €0.11 (down from €0.16 in 1Q 2024). Revenue: €479.9m (up 5.3% from 1Q 2024). Net income: €7.14m (down 34% from 1Q 2024). Profit margin: 1.5% (down from 2.4% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 9.1% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.0%. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 27
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: €0.65 (up from €0.58 in FY 2023). Revenue: €1.87b (up 7.7% from FY 2023). Net income: €43.4m (up 12% from FY 2023). Profit margin: 2.3% (up from 2.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.6%. Revenue is expected to decline by 7.9% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.1%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Nov 26
Now 20% undervalued Over the last 90 days, the stock has risen 6.0% to €12.30. The fair value is estimated to be €15.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to decline by 11% in 2 years. Earnings are forecast to grow by 7.9% in the next 2 years. Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: €0.14 (vs €0.17 in 3Q 2023) Third quarter 2024 results: EPS: €0.14 (down from €0.17 in 3Q 2023). Revenue: €462.8m (up 7.9% from 3Q 2023). Net income: €9.50m (down 15% from 3Q 2023). Profit margin: 2.1% (down from 2.6% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: €0.14 (vs €0.09 in 2Q 2023) Second quarter 2024 results: EPS: €0.14 (up from €0.09 in 2Q 2023). Revenue: €459.4m (up 8.2% from 2Q 2023). Net income: €9.01m (up 57% from 2Q 2023). Profit margin: 2.0% (up from 1.4% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • May 09
First quarter 2024 earnings released: EPS: €0.16 (vs €0.09 in 1Q 2023) First quarter 2024 results: EPS: €0.16 (up from €0.09 in 1Q 2023). Revenue: €455.8m (up 7.7% from 1Q 2023). Net income: €10.8m (up 73% from 1Q 2023). Profit margin: 2.4% (up from 1.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €13.00, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 22x in the Healthcare industry in Germany. Total loss to shareholders of 16% over the past three years. Reported Earnings • Mar 29
Full year 2023 earnings released: EPS: €0.58 (vs €0.38 in FY 2022) Full year 2023 results: EPS: €0.58 (up from €0.38 in FY 2022). Revenue: €1.74b (up 5.0% from FY 2022). Net income: €38.7m (up 54% from FY 2022). Profit margin: 2.2% (up from 1.5% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 29
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €11.10, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 19x in the Healthcare industry in Germany. Total loss to shareholders of 29% over the past three years. Reported Earnings • Nov 10
Third quarter 2023 earnings released: EPS: €0.17 (vs €0.069 in 3Q 2022) Third quarter 2023 results: EPS: €0.17 (up from €0.069 in 3Q 2022). Revenue: €444.1m (up 8.3% from 3Q 2022). Net income: €11.2m (up 130% from 3Q 2022). Profit margin: 2.5% (up from 1.2% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 15
Second quarter 2023 earnings released: EPS: €0.09 (vs €0.16 in 2Q 2022) Second quarter 2023 results: EPS: €0.09 (down from €0.16 in 2Q 2022). Revenue: €424.5m (up 1.1% from 2Q 2022). Net income: €5.73m (down 46% from 2Q 2022). Profit margin: 1.4% (down from 2.5% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 01
Upcoming dividend of €0.15 per share at 1.2% yield Eligible shareholders must have bought the stock before 08 June 2023. Payment date: 13 June 2023. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (3.2%). Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: €0.38 (vs €0.42 in FY 2021) Full year 2022 results: EPS: €0.38 (down from €0.42 in FY 2021). Revenue: €1.67b (up 4.7% from FY 2021). Net income: €25.1m (down 11% from FY 2021). Profit margin: 1.5% (down from 1.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to €15.00 Down from €18.25, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of €15.55. Stock is down 0.8% over the past year. The company is forecast to post earnings per share of €0.25 for next year compared to €0.42 last year. Reported Earnings • Aug 05
Second quarter 2022 earnings released: EPS: €0.16 (vs €0.10 in 2Q 2021) Second quarter 2022 results: EPS: €0.16 (up from €0.10 in 2Q 2021). Revenue: €419.9m (up 5.8% from 2Q 2021). Net income: €10.5m (up 51% from 2Q 2021). Profit margin: 2.5% (up from 1.7% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • May 13
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: €0.01 (down from €0.017 in 1Q 2021). Revenue: €397.8m (up 2.6% from 1Q 2021). Net income: €1.00m (down 10% from 1Q 2021). Profit margin: 0.3% (in line with 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.5%. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Price Target Changed • Apr 27
Price target decreased to €16.50 Down from €18.25, the current price target is provided by 1 analyst. New target price is 9.6% above last closing price of €15.05. Stock is down 2.5% over the past year. The company is forecast to post earnings per share of €0.69 for next year compared to €0.42 last year. Reported Earnings • Nov 13
Third quarter 2021 earnings released: EPS €0.10 (vs €0.09 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: €391.1m (down 2.3% from 3Q 2020). Net income: €6.65m (up 16% from 3Q 2020). Profit margin: 1.7% (up from 1.4% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 09
Second quarter 2021 earnings released: EPS €0.10 (vs €0.003 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €396.9m (up 2.8% from 2Q 2020). Net income: €6.94m (up €6.73m from 2Q 2020). Profit margin: 1.7% (up from 0.1% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Reported Earnings • May 10
First quarter 2021 earnings released: EPS €0.02 (vs €0.066 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €386.6m (up 1.5% from 1Q 2020). Net income: €1.12m (up €5.56m from 1Q 2020). Profit margin: 0.3% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Major Estimate Revision • May 08
Consensus EPS estimates fall to €0.23 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €1.43b to €1.40b. EPS estimate also fell from €0.43 to €0.23. Net income forecast to grow 1,003% next year vs 25% growth forecast for Healthcare industry in Germany. Consensus price target of €18.00 unchanged from last update. Share price rose 2.7% to €16.00 over the past week. Reported Earnings • Mar 26
Full year 2020 earnings released: EPS €0.02 (vs €0.65 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €1.57b (up 5.5% from FY 2019). Net income: €1.45m (down 97% from FY 2019). Profit margin: 0.1% (down from 2.9% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Jan 21
New 90-day low: €15.50 The company is down 6.0% from its price of €16.46 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 7.0% over the same period. Is New 90 Day High Low • Jan 04
New 90-day low: €16.10 The company is down 2.0% from its price of €16.40 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 3.0% over the same period. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS €0.09 The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: €401.9m (up 3.1% from 3Q 2019). Net income: €5.75m (down 66% from 3Q 2019). Profit margin: 1.4% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Sep 19
New 90-day low: €15.98 The company is down 13% from its price of €18.34 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.24 per share.